(Adds details)
June 4 (Reuters) - AstraZeneca said on Friday it had
appointed Alexion's Aradhana Sarin as its new chief
financial officer as it shifts existing CFO Marc Dunoyer to a
new role leading the U.S.-based drugmaker after the pair's
merger.
AstraZeneca agreed to buy Alexion in December in its largest
ever deal, a bet on rare-disease immunology which also includes
a fast-growing cancer medicines unit and a major COVID-19
vaccine.
London-listed AstraZeneca said Sarin's appointment was
conditional upon the completion of its $39 billion buyout of
Alexion.
Dunoyer will become the U.S. drugmaker's chief executive
officer while also being appointed chief strategy officer at
AstraZeneca. He will leave the Anglo-Swedish company's board but
continue to report to CEO Pascal Soriot.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Rashmi
Aich and Patrick Graham)